Core Insights - Aishalon officially listed on the Beijing Stock Exchange on January 21, marking a new chapter in its capital market journey [1] - The company, established in 2015, focuses on the research, production, and sales of disposable medical consumables in rehabilitation care and medical protection [1] Group 1: Business Model and Partnerships - Aishalon specializes in disposable medical consumables such as medical nursing pads and surgical drapes, primarily through ODM/OEM models for international medical device brands [2] - The company has established long-term strategic partnerships with notable brands including Medline Group (USA), Zarys Group (Poland), and Sejong Healthcare (South Korea) [2] - The chairman highlighted that the company has maintained relationships with core clients for over ten years, contributing to stable performance despite high customer concentration [2] Group 2: Innovation and R&D - As of the signing date of the prospectus, Aishalon holds 77 patents, including 21 invention patents, with a continuous increase in R&D investment focused on product performance upgrades and new product development [3] - The company plans to gradually develop its own brand while maintaining its ODM/OEM foundation, aiming for higher market value [3] Group 3: Future Growth and Strategy - The successful issuance and subsequent fundraising will allow Aishalon to expand existing production capacity and increase R&D investment in new medical consumables [4] - The company aims to transition from a single dressing manufacturer to a broader medical consumables manufacturing and service platform, reducing dependency on single products and clients [4] - Aishalon is establishing a global production footprint with a core domestic base and new facilities in Thailand and Morocco, demonstrating strategic vision to adapt to international trade changes and cost pressures [4]

Investment Rating - The investment rating for the company is "Buy," indicating an expected relative increase of over 15% compared to the relevant market index within the next 6-12 months [37]. Core Insights - The company, Aisheren (920050.BJ), specializes in the research, production, and sales of disposable medical consumables in the rehabilitation and medical protection fields. It has established itself as a leading player in the domestic medical dressing industry and has significant competitive advantages in specific segments like medical care pads [2][30]. - The company reported revenues of CNY 574 million in 2022, with a slight growth forecast to CNY 691.6 million in 2024, representing a year-over-year growth of 20.36%. The net profit attributable to the parent company is expected to grow from CNY 63 million in 2022 to CNY 81 million in 2024, with a projected growth rate of 20.54% [8][4]. - The company has a strong partnership with Medline Group, which has been its largest customer since 2007, contributing over 70% of its revenue. This long-term relationship is expected to remain stable [30][31]. Financial Performance - The company achieved revenues of CNY 573.6 million, CNY 574.7 million, and CNY 691.6 million for the years 2022, 2023, and 2024, respectively, with year-over-year growth rates of 0.03%, 0.19%, and 20.36% [4][8]. - The net profit attributable to the parent company for the same years was CNY 62.8 million, CNY 67 million, and CNY 80.7 million, with year-over-year growth rates of -37.12%, 6.62%, and 20.54% [4][8]. Industry Overview - The medical dressing industry is a significant segment of the low-value medical consumables market, accounting for approximately 21%. The global market for medical dressings is projected to grow from USD 9 billion in 2011 to USD 23.5 billion by 2026, driven by increasing demand due to an aging population and rising healthcare expenditures [15][18]. - In China, the medical dressing market is expected to grow from CNY 7 billion in 2011 to CNY 33.3 billion by 2026, indicating a robust growth trajectory supported by improved healthcare infrastructure and rising health awareness among the population [20][18]. Competitive Positioning - Aisheren is positioned among the top ten domestic medical dressing companies and is the largest manufacturer of medical care pads in China. The company differentiates itself through a focus on product research and development, automation in production, and a global supply chain strategy [30][31]. - The company plans to expand its product line to include OTC products and medical collection bags, which are expected to enhance future revenue streams significantly [31][32]. Investment Projects - The company plans to invest CNY 30 million in the construction of a public health medical supplies industrial park, which aims to enhance production capacity and quality control [33][32].